Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gert Van Assche

Showing results (231-240 of 287) with videos related to

Pageof 29
Sort By:
Inflammatory Bowel Diseases|September 18, 2010
Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's diseaseIngrid Arijs, Roel Quintens, Leentje Van Lommel, et al.
Plos One|December 4, 2009
Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatmentIngrid Arijs, Gert De Hertogh, Katleen Lemaire, et al.
Pharmacogenetics and Genomics|March 26, 2009
IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximabCharlotte Magdelaine-Beuzelin, Séverine Vermeire, Margaret Goodall, et al.
Gut|October 16, 2010
Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitisWilliam J Sandborn, Jean Frederic Colombel, Matthew Frankel, et al.
Journal of Crohn'S & Colitis|June 11, 2016
Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel DiseasesJoana Torres, Flavio Caprioli, Konstantinos H Katsanos, et al.
Gut|November 2, 2016
Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UCIngrid Arijs, Gert De Hertogh, Bart Lemmens, et al.
European Journal of Pediatrics|August 2, 2008
Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel diseaseMirjam Bueno de Mesquita, Marc Ferrante, Liesbet Henckaerts, et al.
The American Journal of Gastroenterology|October 3, 2002
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's diseaseSeverine Vermeire, Edouard Louis, An Carbonez, et al.
Nature Communications|June 1, 2017
Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel diseaseMagali de Bruyn, Christine Breynaert, Ingrid Arijs, et al.
Intestinal Research|October 16, 2018
Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approachSilvio Danese, Rupa Banerjee, Jr Fraser Cummings, et al.
Pageof 29

Showing results (231-240 of 287) with videos related to

Sort By:
Pageof 29
Inflammatory Bowel Diseases|September 18, 2010
Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's diseaseIngrid Arijs, Roel Quintens, Leentje Van Lommel, et al.
Plos One|December 4, 2009
Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatmentIngrid Arijs, Gert De Hertogh, Katleen Lemaire, et al.
Pharmacogenetics and Genomics|March 26, 2009
IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximabCharlotte Magdelaine-Beuzelin, Séverine Vermeire, Margaret Goodall, et al.
Gut|October 16, 2010
Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitisWilliam J Sandborn, Jean Frederic Colombel, Matthew Frankel, et al.
Journal of Crohn'S & Colitis|June 11, 2016
Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel DiseasesJoana Torres, Flavio Caprioli, Konstantinos H Katsanos, et al.
Gut|November 2, 2016
Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UCIngrid Arijs, Gert De Hertogh, Bart Lemmens, et al.
European Journal of Pediatrics|August 2, 2008
Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel diseaseMirjam Bueno de Mesquita, Marc Ferrante, Liesbet Henckaerts, et al.
The American Journal of Gastroenterology|October 3, 2002
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's diseaseSeverine Vermeire, Edouard Louis, An Carbonez, et al.
Nature Communications|June 1, 2017
Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel diseaseMagali de Bruyn, Christine Breynaert, Ingrid Arijs, et al.
Intestinal Research|October 16, 2018
Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approachSilvio Danese, Rupa Banerjee, Jr Fraser Cummings, et al.
Pageof 29